Identification of MicroRNAs as Potential Biomarker for Gastric Cancer by System Biological Analysis

Yan, Wenying; Wang, Shouli; Sun, Zhandong; Lin, Yuxin; Sun, Shengwei; Chen, Jiajia; Chen, Weichang

doi:10.1155/2014/901428

Cited by 21 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interesting finding in this meta-analysis was that we did not include any articles that attached attention on multiple miRNAs with regard to OSCC, which may be a possible factor of the limited clinical effect. As expected, in recent sufficient studies, it indicated that a combination of miRNAs (generally 3–5 miRNAs) was more complete indicators than individual miRNAs in various cancers, such as breast cancer, 19 – 21 prostate cancer, 22 , 23 colorectal cancer, 24 – 26 gastric cancer, 27 – 29 lung cancer, 30 , 31 and pancreatic cancer. 32 Therefore, further studies about the comparative diagnosis effect between multiple miRNAs and individual miRNAs on OSCC are needed to be performed.…”

Section: Discussionsupporting

confidence: 76%

Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is one of the most leading causes of cancers worldwide. Due to a low 5-year survival rate, highly effective methods for the early detection of OSCC are totally needed. MicroRNAs (miRNAs), as promising biomarkers, can bring insights into tumorigenesis of oral cancers. However, studies on the accuracy of miRNAs detection in OSCC have inconsistent conclusions, leading us to conduct this meta-analysis. The aim of this study was to systematically review the articles investigating the diagnostic value of miRNAs in OSCC.The PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Web of Science were searched (updated to June 11th, 2015) to identify all articles evaluating the diagnostic yield of miRNAs for OSCC. The pooled sensitivity, specificity, and other diagnostic parameters were used to assess the performance of miRNAs assays on OSCC detection. Statistical analysis was conducted by employing the R software.The present meta-analysis comprised 23 studies from 10 articles, including 598 OSCC patients and 320 healthy individuals, available for analysis. The summary receiver operator characteristic (SROC) curve was plotted. Meanwhile, the pooled diagnostic parameters and the area under curve (AUC) were calculated based on all included studies. The pooled diagnostic parameters calculated from all 23 studies were as follows: pooled sensitivity of 0.759 (95% CI: 0.701–0.809), pooled specificity of 0.773 (95% CI: 0.713–0.823) and AUC of 0.832, which indicates a relatively high diagnostic accuracy of miRNAs in differentiating OSCC patients from healthy controls. Meanwhile, In addition, subgroup analyses were conducted to access the heterogeneity between studies, which is based on specimen (serum/plasma/blood/saliva/ tissue) and ethnicity (Asian/Caucasian).In summary, our meta-analysis suggests that miRNAs might be used in noninvasive screening tests for OSCC, which needs further large-scale studies to be validated.

show abstract

Section: Discussionsupporting

confidence: 76%

Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Nowadays, computational approaches based on systems biology and network science are well performed on detecting microRNA or gene signatures for the diagnosis and treatment of complex diseases such as cancers [ 15 , 16 ], diabetes [ 17 ] and neurodevelopmental disorders [ 18 ]. In particular, Zhang et al introduced a correlation and clustering based framework to identify microRNA-mRNA network modules for differentiating PPCa and MPCa subtypes [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is a fatal malignant tumor among males in the world and the metastasis is a leading cause for PCa death. Biomarkers are therefore urgently needed to detect PCa metastatic signature at the early time. MicroRNAs are small non-coding RNAs with the potential to be biomarkers for disease prediction. In addition, computer-aided biomarker discovery is now becoming an attractive paradigm for precision diagnosis and prognosis of complex diseases.MethodsIn this study, we identified key microRNAs as biomarkers for predicting PCa metastasis based on network vulnerability analysis. We first extracted microRNAs and mRNAs that were differentially expressed between primary PCa and metastatic PCa (MPCa) samples. Then we constructed the MPCa-specific microRNA-mRNA network and screened microRNA biomarkers by a novel bioinformatics model. The model emphasized the characterization of systems stability changes and the network vulnerability with three measurements, i.e. the structurally single-line regulation, the functional importance of microRNA targets and the percentage of transcription factor genes in microRNA unique targets.ResultsWith this model, we identified five microRNAs as putative biomarkers for PCa metastasis. Among them, miR-101-3p and miR-145-5p have been previously reported as biomarkers for PCa metastasis and the remaining three, i.e. miR-204-5p, miR-198 and miR-152, were screened as novel biomarkers for PCa metastasis. The results were further confirmed by the assessment of their predictive power and biological function analysis.ConclusionsFive microRNAs were identified as candidate biomarkers for predicting PCa metastasis based on our network vulnerability analysis model. The prediction performance, literature exploration and functional enrichment analysis convinced our findings. This novel bioinformatics model could be applied to biomarker discovery for other complex diseases.Electronic supplementary materialThe online version of this article (10.1186/s12967-018-1506-7) contains supplementary material, which is available to authorized users.

show abstract

“…In addition, miRNAs have also been shown to target mRNAs in the coding region, 5′-UTR as well as promoter region. This sparked great interests in elucidating the dynamic roles of miRNA that may play in the development and progression of cancer, and led to the rapid expansion of this field 7 8 9 . According to miRBase Release 21 (June 2014), 2,588 unique mature human miRNAs have been identified 5 , 6 .…”

Section: Introductionmentioning

confidence: 99%

May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers?

Tan²,

Fu³

2015

J. Cancer

View full text Add to dashboard Cite

Gastric cancer (GC) is the third leading cause of cancer-related deaths. More than 80% of the diagnosis was made at the advanced stages of the disease, highlighting the urgent demand for novel biomarkers that can be used for early detection. Recently, a number of studies suggest that circulating microRNAs (miRNAs) could be potential biomarkers for GC diagnosis. Cancer-related circulating miRNAs, as well as tissue miRNAs, provide a hopeful prospect of detecting GC at early stages, and the prospective participation of miRNAs in biomarker development will enhance the sensitivity and specificity of diagnostic tests for GC. As miRNAs in blood are stable, their potential value as diagnostic biomarkers in GC has been explored over the past few years. However, due to the inconsistent or sometimes conflicting reports, large-scale prospective studies are needed to validate their potential applicability in GC diagnosis. This review summarizes the current development about potential miRNA biomarkers for GC diagnosis and the obstacles hindering their clinical usage.

show abstract

Identification of MicroRNAs as Potential Biomarker for Gastric Cancer by System Biological Analysis

Cited by 21 publications

References 40 publications

Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma

Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma

Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model

May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers?

Contact Info

Product

Resources

About